Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages

2022 ◽  
pp. 174715
Author(s):  
Elaheh Abdollahi ◽  
Fariborz Keyhanfar ◽  
Ali-Akbar Delbandi ◽  
Reza Falak ◽  
Seyed Javad Hajimiresmaiel ◽  
...  
2013 ◽  
Vol 1833 (6) ◽  
pp. 1553-1561 ◽  
Author(s):  
Renata P. Guedes ◽  
Eduardo Rocha ◽  
Jerome Mahiou ◽  
Herwig P. Moll ◽  
Maria B. Arvelo ◽  
...  

Inflammation ◽  
2014 ◽  
Vol 38 (2) ◽  
pp. 784-799 ◽  
Author(s):  
Sae-Kwang Ku ◽  
Wei Zhou ◽  
Wonhwa Lee ◽  
Min-Su Han ◽  
MinKyun Na ◽  
...  

BMB Reports ◽  
2012 ◽  
Vol 45 (3) ◽  
pp. 200-205 ◽  
Author(s):  
Tae-Hoon Kim ◽  
Sae-Kwang Ku ◽  
In-Chul Lee ◽  
Jong-Sup Bae

2005 ◽  
Vol 59 (s148) ◽  
pp. 3-13
Author(s):  
L. Mussoni ◽  
S. Colli ◽  
M. Brambilla ◽  
A. Banas ◽  
S. Eligini ◽  
...  

2017 ◽  
Vol 8 (8) ◽  
pp. 2905-2914 ◽  
Author(s):  
Francisco J. G. Muriana ◽  
Sergio Montserrat-de la Paz ◽  
Ricardo Lucas ◽  
Beatriz Bermudez ◽  
Sara Jaramillo ◽  
...  

Novel biological activities for tyrosol metabolites on human endothelial cells.


Author(s):  
Rougang Li ◽  
Arunachalam Chinnathambi ◽  
Sulaiman Ali Alharbi ◽  
Omar H. M. Shair ◽  
Vishnu Priya Veeraraghavan ◽  
...  

2010 ◽  
Vol 298 (6) ◽  
pp. C1538-C1548 ◽  
Author(s):  
Lesley E. Smythies ◽  
C. Roger White ◽  
Akhil Maheshwari ◽  
M. N. Palgunachari ◽  
G. M. Anantharamaiah ◽  
...  

HDL and its major protein component apolipoprotein A-I (apoA-I) exert anti-inflammatory effects, inhibit monocyte chemotaxis/adhesion, and reduce vascular macrophage content in inflammatory conditions. In this study, we tested the hypothesis that the apoA-I mimetic 4F modulates the function of monocyte-derived macrophages (MDMs) by regulating the expression of key cell surface receptors on MDMs. Primary human monocytes and THP-1 cells were treated with 4F, apoA-I, or vehicle for 7 days and analyzed for expression of cell surface markers, adhesion to human endothelial cells, phagocytic function, cholesterol efflux capacity, and lipid raft organization. 4F and apoA-I treatment decreased the expression of HLA-DR, CD86, CD11b, CD11c, CD14, and Toll-like receptor-4 (TLR-4) compared with control cells, suggesting the induction of monocyte differentiation. Both treatments abolished LPS-induced mRNA for monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), regulated on activation, normal T-expressed and presumably secreted (RANTES), IL-6, and TNF-α but significantly upregulated LPS-induced IL-10 expression. Moreover, 4F and apoA-I induced a 90% reduction in the expression of CD49d, a ligand for the VCAM-1 receptor, with a concurrent decrease in monocyte adhesion (55% reduction) to human endothelial cells and transendothelial migration (34 and 27% for 4F and apoA-I treatments) compared with vehicle treatment. In addition, phagocytosis of dextran-FITC beads was inhibited by 4F and apoA-I, a response associated with reduced expression of CD32. Finally, 4F and apoA-I stimulated cholesterol efflux from MDMs, leading to cholesterol depletion and disruption of lipid rafts. These data provide evidence that 4F, similar to apoA-I, induces profound functional changes in MDMs, possibly due to differentiation to an anti-inflammatory phenotype.


2020 ◽  
Vol 64 (20) ◽  
pp. 2000382
Author(s):  
Ella J. Baker ◽  
Carina A. Valenzuela ◽  
Wies T.M. Dooremalen ◽  
Leyre Martínez‐Fernández ◽  
Parveen Yaqoob ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document